Journal of Diabetes: Ushering in Volume 10

As developments progress in the understanding and treatment of diabetes, we take a moment to reflect on the Journal as it enters its 10th year.

It has been a decade of tremendous change. In 2009, the diabetes community was recovering from the shock of ACCORD trial: 257 deaths over 3.5 years with an achieved HbA1c of 6.4% among 5128 intensively treated the high cardiovascular (CV) risk patients, compared with 203 deaths with an achieved HbA1c of 7.5% among 5123 having “standard treatment.”1 Today, we see evidence of reduction in CV outcomes with a variety of treatments, including thiazolidinediones, sodium–glucose transport inhibitors, and glucagon-like peptide-1 receptor agonists, suggesting that some of the adverse effects seen in ACCORD were related to older approaches to treatment, and that new approaches may offer new paradigms (Fig. 1).

The Journal has published nearly 800 papers (Fig. 2a), with contributions from 86 countries, on topics ranging from treatment approaches, to effects of sleep abnormality, to cost issues and epidemiologic patterns, to patterns of fat distribution, to diabetic neuropathy, nephropathy, and retinopathy, to CV conditions, to dyslipidemia, to obesity, to insulin secretory function, to exercise, to diet, to supplements and herbal treatments, to infections, to malignancy, to adherence and psychosocial factors… and the list goes on, reflecting the tremendous complexity of the condition and its implications. The ongoing interest in these publications has been gratifying, and we are happy that in 2017 more than 100 000 article downloads had been registered (Fig. 2b) and that in 2016 there were more than 1100 citations of articles in the Journal, giving us an Impact Factor of 3.039.

千里之行始于足下, the journey of a thousand miles begins with a single step, and we have taken many small steps to reach Volume 10. As we begin Volume 10, we thank all those whose contributions to the Journal have been crucial to its success: our authors, our reviewers, our fellow editors, and, most importantly, our readers.

随着人们对糖尿病的认识与治疗的不断进展,  我们即将迎来创刊第十年,  值此之际,  让我们一起回顾一下本刊所走过的历程。

这十年间发生了巨大的变化。从2009年开始,  糖尿病学界逐渐从ACCORD试验的冲击中恢复过来:5128名具有高危心血管(CV)风险的患者经过3.5年的强化治疗后HbA1c达到了6.4%,  但却有257名患者死亡,  而5123名“标准治疗”的对照组患者HbA1c达到了7.5%,  相应的死亡人数只有203名¹。到了今天,  我们又看到了许多治疗药物降低心血管结果的证据,  包括噻唑烷二酮、钠-葡萄糖共转运体抑制剂以及胰高血糖素样肽-1受体激动剂,  这意味着在ACCORD试验中看到的某些不良作用与旧的治疗方法有关,  而新的治疗方法为我们提供了新的治疗流程(图1)。

本刊已经发表了将近800篇文章(图 2a),  供稿的作者来自86个国家,  文章主题包括治疗方法、睡眠异常的影响、成本问题与流行病学模式、脂肪分布模式、糖尿病神经病变、肾病以及视网膜病变、心血管状况、血脂紊乱、肥胖、胰岛素分泌功能、运动、饮食、补充剂与草药治疗、感染、恶性肿瘤、依从性与心理社会因素…,  主题名单还在不断地增加,  这表明糖尿病以及相关情况都非常复杂。我们欣喜地看到读者对本刊发表文章的兴趣在不断增加,  本刊在2017年被登录下载的文章超过了100000篇(图 2b),  2016年本刊被引用的文章超过了1100篇,  这使得我们的影响因子达到了3.039。

千里之行始于足下,  我们从创刊至今力争踏实走好每一步。当我们开启第10卷的时候,  我们要感谢所有对本刊做出贡献的人,  他们对我们迈向成功至关重要:我们的作者、我们的审稿专家、我们的编辑同事,  以及我们最重要的读者。